DE69716605T2 - Anti-chlamydia verfahren und mittel - Google Patents

Anti-chlamydia verfahren und mittel

Info

Publication number
DE69716605T2
DE69716605T2 DE69716605T DE69716605T DE69716605T2 DE 69716605 T2 DE69716605 T2 DE 69716605T2 DE 69716605 T DE69716605 T DE 69716605T DE 69716605 T DE69716605 T DE 69716605T DE 69716605 T2 DE69716605 T2 DE 69716605T2
Authority
DE
Germany
Prior art keywords
chlamydia
chlamydial infection
bpi
bactericidal
inducing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69716605T
Other languages
English (en)
Other versions
DE69716605D1 (de
Inventor
H Lambert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xoma Technology Ltd USA
Original Assignee
Xoma Technology Ltd USA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma Technology Ltd USA filed Critical Xoma Technology Ltd USA
Application granted granted Critical
Publication of DE69716605D1 publication Critical patent/DE69716605D1/de
Publication of DE69716605T2 publication Critical patent/DE69716605T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1751—Bactericidal/permeability-increasing protein [BPI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
DE69716605T 1996-08-09 1997-08-07 Anti-chlamydia verfahren und mittel Expired - Fee Related DE69716605T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/694,843 US5888973A (en) 1996-08-09 1996-08-09 Anti-chlamydial uses of BPI protein products
PCT/US1997/013810 WO1998006415A2 (en) 1996-08-09 1997-08-07 Anti-chlamydial methods and materials

Publications (2)

Publication Number Publication Date
DE69716605D1 DE69716605D1 (de) 2002-11-28
DE69716605T2 true DE69716605T2 (de) 2003-06-26

Family

ID=24790487

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69716605T Expired - Fee Related DE69716605T2 (de) 1996-08-09 1997-08-07 Anti-chlamydia verfahren und mittel

Country Status (10)

Country Link
US (3) US5888973A (de)
EP (1) EP0918533B1 (de)
JP (1) JP2001500117A (de)
CN (1) CN1232401A (de)
AT (1) ATE226442T1 (de)
AU (1) AU741480B2 (de)
CA (1) CA2263181C (de)
DE (1) DE69716605T2 (de)
NZ (1) NZ334041A (de)
WO (1) WO1998006415A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
US5888973A (en) * 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
WO1998006435A2 (en) * 1996-08-14 1998-02-19 Vanderbilt University COMPOSITIONS OF ANTICHLAMYDIAL AGENTS FOR THE DIAGNOSIS AND MANAGEMENT OF INFECTION CAUSED BY $i(CHLAMYDIA)
US6482796B2 (en) 1996-11-01 2002-11-19 Xoma Corporation Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
US6884784B1 (en) * 1997-05-06 2005-04-26 Vanderbilt University Diagnosis and management of infection caused by chlamydia
US6093573A (en) * 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
US6013631A (en) * 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
US6310073B1 (en) * 1998-07-28 2001-10-30 Queen's University At Kingston Methods and compositions to treat glycosaminoglycan-associated molecular interactions
US7056893B2 (en) * 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
US6239113B1 (en) * 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
US6153584A (en) * 1999-04-01 2000-11-28 Levy; Ofer Therapeutic uses of BPI protein products in BPI-deficient humans
US7041644B2 (en) 1999-04-01 2006-05-09 Xoma Technology Therapeutic uses of BPI protein products in BPI-deficient humans
JP2004517865A (ja) * 2000-12-01 2004-06-17 ゾーマ テクノロジー リミテッド Ｂｐｉタンパク質産物またはｂｐｉインヒビターを使用する、周皮細胞増殖の調節
AU2003239438A1 (en) * 2002-05-15 2003-12-02 University Of Washintgon Method of screening anti-bacterial agents for effectiveness in treating persistent intracellular infections
US8394379B2 (en) * 2003-05-15 2013-03-12 Iogenetics, Llc Targeted cryptosporidium biocides
US8703134B2 (en) 2003-05-15 2014-04-22 Iogenetics, Llc Targeted cryptosporidium biocides
US20050014932A1 (en) * 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
US20060046970A1 (en) * 2004-08-31 2006-03-02 Insite Vision Incorporated Topical otic compositions and methods of topical treatment of prevention of otic infections
WO2006113526A2 (en) * 2005-04-15 2006-10-26 The Regents Of The University Of California Prevention of chlamydia infection using a protective antibody
EP1741440A1 (de) 2005-07-08 2007-01-10 Mellitus S.L. Verwendung von BPI-proteine zur Behandlung von stoffwechselbedingten Erkrankungen und Herzkreislaufstörungen
GB201319620D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Immunosuppressive agents and their use in therapy
GB201319621D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Antimicrobial agents and their use in therapy
US10602795B2 (en) 2017-01-26 2020-03-31 Bell Sports, Inc. Helmet comprising a segmented shell

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1659132A1 (de) * 1987-08-11 2006-05-24 New York University BPI Fragmente
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
US5576292A (en) * 1987-08-11 1996-11-19 New York University Biologically active bactericidal/permeability-increasing protein fragments
US5334584A (en) * 1989-02-14 1994-08-02 Incyte Pharamaceuticals, Inc. Recombinant, non-glycosylated bpi protein and uses thereof
US5171739A (en) * 1989-02-14 1992-12-15 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and preventation thereof using a BPI protein
US5089274A (en) * 1989-02-14 1992-02-18 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
US5234912A (en) * 1989-02-14 1993-08-10 Incyte Pharmaceuticals, Inc. Pharmaceutical compositions comprising recombinant BPI proteins and a lipid carrier and uses thereof
US5308834A (en) * 1989-02-14 1994-05-03 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and prevention thereof using a BPI protein
EP0563222B1 (de) * 1990-12-03 1998-02-25 New York University Biologisch aktive bakterizide/permeabilitätserhöhende proteinbruchstücke
EP0605653A4 (de) * 1991-09-26 1995-03-15 Incyte Pharma Inc Neue art eines liposaccharid bindendes protein (lbp).
US5643570A (en) * 1992-05-19 1997-07-01 Xoma Corporation BPI-immunoglobulin fusion proteins
WO1993023540A2 (en) * 1992-05-19 1993-11-25 Xoma Corporation Improved methods for the preparation of endotoxin-binding proteins
EP0682524B1 (de) * 1993-02-02 2001-10-04 XOMA Technology Ltd. Arzneizusammensetzungen enthaltend ein bakterizides permeabilität erhöhendes protein und ein tensid
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
US5348942A (en) * 1993-03-12 1994-09-20 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein products
US5733872A (en) * 1993-03-12 1998-03-31 Xoma Corporation Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
MX9401807A (es) * 1993-03-12 1995-01-31 Xoma Corp Usos terapeuticos de productos de proteina que incrementan lapermeabilidad/bactericidas.
ATE165976T1 (de) * 1993-03-12 1998-05-15 Xoma Corp Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
AU694108B2 (en) * 1993-03-12 1998-07-16 Xoma Corporation Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
AU6522794A (en) * 1993-03-22 1994-10-11 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein and lipopolysaccharide binding protein levels and ratios thereof in diagnosis
CA2161971A1 (en) * 1993-04-30 1994-11-10 Randal W. Scott Recombinant bpi-based and lbp-based proteins, nucleic acid molecules encoding same, methods of producing same, and uses thereof
AU7175694A (en) * 1993-06-17 1995-01-17 Xoma Corporation Lipopolysaccharide binding protein derivatives
CA2166488A1 (en) * 1993-07-02 1995-01-12 Marian N. Marra Glycosylated and non-glycosylated bactericidal/permeability increasing proteins, and methods for producing same
WO1995002414A1 (en) * 1993-07-14 1995-01-26 Xoma Corporation Method for potentiating bpi protein product bactericidal activity by administration of lbp protein products
CN1133634A (zh) * 1993-09-22 1996-10-16 爱克斯欧玛公司 定量体液中的bpi的方法
DE69430823T2 (de) * 1993-09-22 2003-02-20 Xoma Technology Ltd Verfahren zur behandlung von gram-negativen bakterien infektion durch verabreichung von bakterientötendem/durchlässigkeiterhöhendem (bpi) proteinprodukt und antibiotikum
US5466580A (en) * 1993-09-22 1995-11-14 Xoma Corporation Method for quantifying BPI in body fluids
ATE269099T1 (de) * 1993-10-15 2004-07-15 Xoma Technology Ltd Bpi-protein-produkte für definierte funktionen des reticuloendothelialen systems
EP0754049B1 (de) * 1994-01-14 2002-04-03 XOMA Technology Ltd. Antifungaleverfahren und mitteln
DK0754050T3 (da) * 1994-01-14 2002-10-21 Xoma Technology Ltd Anti-gram-positive bakterielle fremgangsmåder og materialer
US5484705A (en) * 1994-01-24 1996-01-16 Xoma Corporation Method for quantifying lipopolysaccharide binding protein
US5643875A (en) * 1994-01-24 1997-07-01 Friedmann; Nadav Human therapeutic uses of bactericidal/permeability increasing (BPI) protein products
US5447913A (en) * 1994-03-11 1995-09-05 Xoma Corporation Therapeutic uses of bactericidal/permeability-increasing protein dimer products
US5578568A (en) * 1994-04-22 1996-11-26 Xoma Corporation Method of treating conditions associated with intestinal ischemia/reperfusion
US5532216A (en) * 1994-06-24 1996-07-02 Incyte Pharmaceuticals, Inc. Neutralization of non-lipopolysaccharide compounds by bactericidal/permeability-increasing protein
US5646114A (en) * 1994-07-11 1997-07-08 Xoma Corporation Anti-protozoan methods
JPH10508576A (ja) * 1994-09-15 1998-08-25 ゾーマ コーポレイション 抗真菌性ペプチド
US5912228A (en) * 1995-01-13 1999-06-15 Xoma Corporation Therapeutic compositions comprising bactericidal/permeability-increasing (BPI) protein products
US5494896A (en) * 1995-03-31 1996-02-27 Xoma Corporation Method of treating conditions associated with burn injuries
JP2001520631A (ja) * 1995-07-20 2001-10-30 ゾーマ コーポレイション 抗真菌性ペプチド
JP2000501386A (ja) * 1995-11-14 2000-02-08 ゾーマ コーポレイション 角膜損傷に関連する病態を処置するための、殺菌性／透過性増強（ｂｐｉ）タンパク質
US5686414A (en) * 1995-11-14 1997-11-11 Xoma Corporation Methods of treating conditions associated with corneal transplantation
US5741779A (en) * 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
DE69703689T2 (de) * 1996-05-10 2001-05-10 Xoma Technology Ltd Therapeutische anwendungen von bpi-protein-produkten zur behandlung von humaner meningococcämia
US5746753A (en) * 1996-05-13 1998-05-05 Boston Scientific Corporation Needle grasping apparatus
AU736096B2 (en) * 1996-05-23 2001-07-26 Xoma Corporation Therapeutic uses of BPI protein products in humans with hemorrhage due to trauma
US5888973A (en) * 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products

Also Published As

Publication number Publication date
EP0918533A2 (de) 1999-06-02
WO1998006415A2 (en) 1998-02-19
CA2263181C (en) 2003-03-18
US6583116B1 (en) 2003-06-24
ATE226442T1 (de) 2002-11-15
CN1232401A (zh) 1999-10-20
NZ334041A (en) 2000-10-27
CA2263181A1 (en) 1998-02-19
AU3909497A (en) 1998-03-06
DE69716605D1 (de) 2002-11-28
WO1998006415A3 (en) 1998-05-14
JP2001500117A (ja) 2001-01-09
EP0918533B1 (de) 2002-10-23
US5888973A (en) 1999-03-30
AU741480B2 (en) 2001-11-29
US6162788A (en) 2000-12-19

Similar Documents

Publication Publication Date Title
DE69716605T2 (de) Anti-chlamydia verfahren und mittel
DE69526216D1 (de) Antifungaleverfahren und mitteln
ATE348113T1 (de) Rekombinanter anti-cd4 antikörper zur menschlichen behandlung
DE69524682T2 (de) Mittel zur Behandlung von Wunden
DE59606267D1 (de) Mittel zur Haarbehandlung
ATE240743T1 (de) Verfahren und substanzen gegen protozoen
DE69727142D1 (de) Verwendung eines bpi proteinproduktes als antithrombotisches mittel
ATE244549T1 (de) Mittel zur behandlung von haar
DE69630947D1 (de) Mittel zur schmerzbehandlung
DE69609868T2 (de) Neue steroidester zur behandlung von hauterkrankungen
DE69703689T2 (de) Therapeutische anwendungen von bpi-protein-produkten zur behandlung von humaner meningococcämia
DE69628852D1 (de) Therapeutische medizinische kleidung für narben und entsprechendes verfahren
ZA969130B (en) Diagnostics and treatments of periodontal disease
DE69509843T2 (de) Apparat zur Behandlung z.B. von Poststücken
DE69613386T2 (de) Carbostyrilderivat zur behandlung von ophthalmologischen erkrankungen
DE69631282D1 (de) Blutverarbeitungssystem und verfahren
DE59608075D1 (de) Intrakorporales behandlungssystem
ATE156346T1 (de) Mittel zur haarbehandlung
DE59609353D1 (de) Mittel zur subkutanen Verabreichung von Protein C
DE29510525U1 (de) Mittel zur Haarbehandlung
DE9412203U1 (de) Mittel zur Haarbehandlung
DE29512336U1 (de) Haarbehandlungsmittel

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee